{"entity":{"id":"profound-mced","kind":"trial","name":"PROFOUND (Weihe multi-omic multi-cancer case-control study)","aka":["PROFOUND"],"tldr":"A Chinese case-control study of about 16,700 people building a multi-omic blood test for several cancers.","summary":"PROFOUND (NCT06217900) is an observational study sponsored by Shanghai Weihe Medical Laboratory Co., Ltd with Peking University People's Hospital. It develops and validates in a blinded set a machine-learning multi-cancer early detection model from blood multi-omic analysis.\n\nThe registry record, read on 29 October 2026, gives its status as active, not recruiting, with an estimated 16,666 participants, a start on 28 December 2023 and primary completion expected on 31 October 2026.","status":"active","asOf":"2026-10-29","links":[{"label":"ClinicalTrials.gov NCT06217900","url":"https://clinicaltrials.gov/study/NCT06217900"}],"tags":[],"related":[],"cancers":[],"sections":["early-detection"],"technologies":["mced","liquid-biopsy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06217900","phase":"observational","setting":"People newly diagnosed with cancer and people without cancer at Chinese hospitals, developing and blind-testing a multi-omic machine-learning model","sponsor":"Shanghai Weihe Medical Laboratory Co., Ltd. with Peking University People's Hospital","started":"2023-12-28","startedType":"actual","enrolled":16666,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/profound-mced/","neighbours":{"section":[{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"}]}}